Keynote Speaker

Hans Clevers, Roche, Switzerland
Clevers.jpg

Hans Clevers obtained his MD degree in 1984 and his PhD degree in 1985 from the University Utrecht, the Netherlands. His postdoctoral work (1986-1989) was done with Cox Terhorst at the Dana-Farber Cancer Institute of the Harvard University, Boston, USA.

From 1991-2002 Hans Clevers was Professor in Immunology at the University Utrecht and, since 2002, Professor in Molecular Genetics. From 2002-2012 he was director of the Hubrecht Institute in Utrecht. From 2012-2015 he was President of the Royal Netherlands Academy of Arts and Sciences (KNAW). From 2015 - June 2019 he was Director Research of the Princess Maxima Center for pediatric oncology. He continues to run his lab in the Hubrecht Institute.

Throughout his career, he has worked on the role of Wnt signaling in stem cells and cancer. His discoveries include TCF as the nuclear Wnt effector, the role of Wnt in adult stem cell biology and of Wnt pathway mutations in colon cancer, Lgr5 as a marker of multiple novel types of adult stem cells and as receptor for the Wnt-amplifying R-spondins, and –finally- a method to grow ever-expanding mini-organs (‘organoids’) from Lgr5 stem cells derived from a range of healthy or diseased human tissues. This has led to over 750 publications and >90,000 citations

Hans Clevers is member of the Royal Netherlands Academy of Arts and Sciences (2000), of the American Academy of Arts and Sciences (2012) and the National Academy of Sciences of the USA (2014), the Academie des Sciences (2016) and the Orden pour le Merite der Wissenschaften und Kuenste (2017).

He is the recipient of multiple awards, including the Dutch Spinoza Award in 2001, the Swiss Louis Jeantet Prize in 2004, the German Meyenburg Cancer Research Award in 2008, the German Ernst Jung-Preis für Medizin in 2011, the French Association pour la Recherche sur le Cancer (ARC) Léopold Griffuel Prize, the Heineken Prize (2012), the Breakthrough Prize in Life Sciences (2013), the 2015 ISSCR McEwen Award for Innovation and the Academy Professor Prize (2015), and the Körber European Science Prize (2016).

He is Chevalier de la Legion d’Honneur since 2005, Knight in the Order of the Netherlands Lion since 2012 and German prize.

As of March 18th, 2022, Hans Clevers is the Head of Pharma Research and Early Development and a Member of the Enlarged Corporate Executive Committee of  F.Hoffmann-La Roche Ltd, in Basel, Switzerland.

« Go Back

Register Here Submit Abstract
In collaboration with
 
In collaboration with
CIRM
Supporting Publications
Premium sponsor
 
Cell Mentor
Silver Sponsor
 
stemcell
Exhibitors
 
  • BioLamina
  • CBC
  • cellcolabs
  • cellcolabs
  • defined-bioscience
  • synthego
Financial Support Available

Vector builder